Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: JAMA Oncol. 2016 Mar 1;2(3):330–339. doi: 10.1001/jamaoncol.2015.4508

TABLE 2.

Adjusted/weighted and unadjusted/unweighted patient and tumor characteristics of the National Cancer Database study, by delay interval. Variables also included in the analysis, but not displayed below, are region, income, education, year of diagnosis, facility/cancer program type, mean distance to facility, and analytic case type. These are delineated in eTable 5 for space reasons.

Characteristic Adjusted % (Unadjusted %)* unless otherwise specified
≤30 days 31–60 days 61–90 days 91–120 days 121–180 days
Total Patients 80,505 28,832 4,697 1,152 604
Mean age in years 60.4 (60.1) 60.5 (60.8) 60.9 (60.8) 60.6 (60.7) 60.3 (61.3)
Gender
 Female 99.1 (99.0) 99.1 (99.3) 98.7 (99.3) ** **
 Male 0.9 (1.0) 0.9 (0.7) 1.3 (0.7) ** **
Race
 White 82.8 (85.4) 82.9 (79.6) 82.4 (71.0) 80.7 (58.5) 85.0 (57.0)
 Black 9.2 (7.6) 9.1 (11.2) 9.2 (16.7) 9.6 (23.1) 8.5 (26.0)
 Asian 2.1 (2.0) 2.2 (2.3) 2.3 (2.4) 2.2 (3.0) 1.7 (3.8)
 Hispanic 4.1 (3.2) 4.0 (5.1) 4.1 (8.2) 5.0 (12.5) 3.5 (10.8)
 Other/Unknown 1.8 (1.8) 1.8 (1.8) 1.9 (1.8) 2.5 (2.9) 1.4 (2.5)
Charlson Comorbidity Score
 0 88.1 (88.8) 88.1 (87.4) 87.9 (85.6) 86.9 (84.2) 88.0 (83.6)
 1 10.0 (9.6) 10.1 (10.5) 10.0 (11.4) 10.9 (11.9) 10.0 (12.4)
 ≥2 1.8 (1.7) 1.9 (2.1) 2.1 (3.0) 2.3 (3.9) 2.0 (4.0)
Setting§
 Large metropolitan 51.3 (47.9) 51.2 (57.9) 51.3 (63.1) 52.9 (67.5) 46.9 (68.9)
 Metropolitan 32.6 (34.5) 32.7 (29.1) 32.5 (25.8) 30.9 (23.0) 35.2 (21.5)
 Urban 6.5 (7.0) 6.5 (5.6) 6.3 (4.9) 6.3 (3.8) 7.6 (4.3)
 Less Urban/Rural 9.6 (10.7) 9.6 (7.5) 9.9 (6.2) 9.9 (5.6) 10.3 (5.3)
Invasive Histology
 Ductal 89.2 (89.5) 89.3 (88.7) 88.9 (88.6) 87.4 (87.7) 87.9 (87.3)
 Lobular 8.1 (7.7) 8.1 (8.7) 8.0 (8.6) 9.5 (9.6) 9.7 (8.9)
 Other/unknown 2.7 (2.8) 2.7 (2.6) 3.2 (2.8) 3.1 (2.8) 2.4 (3.8)
Grade
 Well differentiated 21.0 (20.4) 21.0 (22.5) 20.9 (22.5) 21.4 (18.4) 19.7 (17.7)
 Moderately differentiated 39.7 (39.4) 39.8 (40.3) 40.1 (40.5) 42.9 (43.0) 40.9 (35.6)
 Poorly differentiated 32.6 (33.8) 32.5 (30.2) 31.9 (28.9) 29.0 (29.9) 32.8 (33.8)
 Undifferentiated/Anaplastic 0.9 (0.9) 0.8 (0.8) 0.9 (1.0) 0.6 (1.7) 0.5 (2.3)
 Unknown 5.8 (5.5) 5.9 (6.2) 6.3 (7.1) 6.1 (7.0) 6.1 (10.6)
Mean tumor size in cm 2.1 (2.1) 2.0 (2.0) 2.1 (2.1) 2.1 (2.1) 2.2 (3.4)
AJCC Stage
 I 52.1 (51.6) 52.2 (53.6) 51.9 (52.1) 50.2 (50.4) 48.0 (41.6)
 II 37.2 (37.6) 37.0 (36.3) 37.2 (35.6) 39.3 (34.9) 40.4 (38.9)
 III 10.8 (10.7) 10.8 (10.1) 11.0 (12.4) 10.5 (14.7) 11.7 (19.5)
Surgical Margins: Residual Tumor
 None 94.6 (94.8) 94.6 (94.4) 94.3 (93.6) 94.6 (91.1) 95.6 (92.4)
 Residual 4.3 (4.2) 4.3 (4.3) 4.7 (4.6) 4.2 (6.4) 3.3 (4.8)
 Other/Unknown 1.1 (1) 1.1 (1.3) 1.1 (1.8) 1.2 (2.5) 1 (2.8)
Mean # Nodes Examined 7.8 (7.8) 7.8 (7.7) 7.8 (8.2) 7.8 (8.7) 8.5 (9.4)
Mean # Nodes Positive 1.2 (1.2) 1.2 (1.1) 1.2 (1.3) 1.2 (1.4) 1.4 (1.9)
Surgery Type
 Breast Conservation 62.9 (65.4) 63 (58.9) 63.7 (51.9) 60.3 (48.2) 64.4 (45.5)
 Mastectomy 37.1 (34.6) 37 (41.1) 36.3 (48.1) 39.7 (51.8) 35.6 (54.5)
Chemotherapy Use
 Yes 37.1 (34.6) 37 (41.1) 36.3 (48.1) 39.7 (51.8) 35.6 (54.5)
 No 62.9 (65.4) 63 (58.9) 63.7 (51.9) 60.3 (48.2) 64.4 (45.5)
Radiotherapy Use
 Yes 62.8 (65.5) 62.7 (58.7) 63.3 (50.6) 60.4 (44.8) 65.4 (40.9)
 No 37.2 (34.5) 37.3 (41.3) 36.7 (49.4) 39.6 (55.2) 34.6 (59.1)
Endocrine Therapy Use
 Yes 52.5 (53.1) 52.5 (52.8) 51.5 (48) 51.7 (43.1) 53.5 (36.6)
 No 47.5 (46.9) 47.5 (47.2) 48.5 (52) 48.3 (56.9) 46.5 (63.4)
Insurance Type
 None 2.0 (1.8) 2.0 (2.2) 2.0 (3.3) 1.9 (5.1) 1.9 (5.5)
 Private 16.5 (17.8) 16.5 (13.9) 16.6 (12.1) 17.2 (10) 17.6 (9.6)
 Managed Care 39.2 (39.2) 39 (40.6) 37.1 (36.5) 38.3 (33.9) 36.4 (30.1)
 Medicaid 4.3 (3.5) 4.3 (5.2) 4.6 (8.2) 4.8 (11.1) 4.5 (10.9)
 Medicare 35 (34.6) 35.3 (35.4) 37.2 (35.7) 35.5 (33.5) 38.1 (36.9)
 Other Government/Unknown 3.0 (3) 2.9 (2.7) 2.4 (4.2) 2.4 (6.3) 1.6 (7.0)
*

Totals may vary from 100% due to rounding.

**

Cells have been deleted as per NCDB requirements to censor cells containing <11 individuals, or other cells that make such cells calculable.

Charlson scores of ≥2 are collapsed together into one group and so mean Charlson scores for NCDB data cannot be calculated.

§

Setting definitions: Large metropolitan = counties of metropolitan areas of ≥1,000,000; metropolitan = counties in metropolitan areas of <250,000–1,000,000; urban = urban population of ≥20,000 adjacent or nonadjacent to a metropolitan area; less urban = urban population of 2,500–19,999 adjacent or nonadjacent to a metropolitan area; rural = completely rural or <2,500 urban population, adjacent or nonadjacent to a metropolitan area.

AJCC Stage: 5rd and 6th editions were combined. Substages (e.g. IIA, IIB) were collapsed to minimize differences between these AJCC Editions.